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Purpose: Transforming growth factor β (TGFb) is known to cause fibrosis in the cornea 
following injury and/or infection. Effective reduction in corneal fibrosis has been reported by 
inhibiting TGFb activity. However, associated molecular mechanism is still unknown. The aim 
of study was to test the hypothesis that the alteration in SMAD signaling is a novel approach for 
treating corneal fibrosis using an established in vitro model. 
Methods: Primary corneal fibroblast (HSF) cultures generated from donor human corneas 
were exposed to TGFβ1 (1ng/ml). To test the hypothesis gene transfer approach was used. 
Decorin (a natural inhibitor of TGFb) cDNA was introduced into HSF with non-viral (lipids) 
or viral (AAV5) vector. Real-time PCR, immunoblotting and/or immunocytochemistry 
measured the markers of fibrosis (aSMA, F-actin and fibronectin). Immunoblotting and/or 
immunocytochemistry examined the non-phosphorylated and phosphorylated forms of SMAD2 
and SMAD7 proteins. 
Results: TGFβ1 treatment significantly induced myofibroblast formation and fibrosis in the 
HSF as shown by mRNA and protein levels of aSMA (myofibroblasts marker). Decorin-
transfected HSF showed significant decrease in TGFβ1-induced fibrosis in the human cornea 
in vitro. Detection of significant increase in Smad7 and decrease in Smad2 levels in decorin-
overexpressing clones was detected compared to naked vector-transfected clones. The effects 
were more pronounced in AAV-transduced clones than the plasmid-transfected clones, most 
likely due to the higher transgene delivery with AAV than the plasmid vector. 
Conclusions: Inhibition of SMAD signaling pathway can be used for developing mechanism-
based newer anti-fibrotic therapies for the cornea. 
